Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb

 
• By Jo Shorthouse

Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.

Cycling
Novartis pushes ahead with dermatology

More from Business

More from Scrip